Top

Published in:

01-02-2013 | Rapid Communication

Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011

Authors: Anne Hackenberg, Gökhan Arman-Kalcek, Jens Hiller, Gülsah Gabriel

Published in: Medical Microbiology and Immunology | Issue 1/2013

Abstract

Location- and age-specific prevalence of antibodies against 2009 pandemic influenza A (H1N1) virus were determined in sera of blood donors collected during winter 2010/2011 in Germany. Prevalence of antibodies at protective titres (HI ≥1:40) varied significantly between cities (24.13–83.67 %) throughout all age groups. However, high level antibodies (HI >1:80) were most prevalent among young individuals (18–29 and 30–39 years). Overall, this study demonstrates that older people (50–59 and 60–70 years) are no longer more likely to present protective antibody titres against 2009 pandemic influenza A (H1N1) virus than younger individuals. Furthermore, our data show a highly variable immunity among the German population in different major cities almost 2 years after the detection of first cases in Germany.

Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, Ghani AC, Ferguson NM, Rambaut A, Pybus OG, Lopez-Gatell H, Alpuche-Aranda CM, Chapela IB, Zavala EP, Guevara DM, Checchi F, Garcia E, Hugonnet S, Roth C (2009) Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324:1557–1561PubMedCrossRef

Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, Lopez-Gatell H, Olivera H, Lopez I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197–201PubMedCrossRef

Poggensee G, Gilsdorf A, Buda S, Eckmanns T, Claus H, Altmann D, Krause G, Haas W (2010) The first wave of pandemic influenza (H1N1) 2009 in Germany: from initiation to acceleration. BMC Infect Dis 10:155PubMedCrossRef

Wilking H, Buda S, von der Lippe E, Altmann D, Krause G, Eckmanns T, Haas W (2010) Mortality of 2009 pandemic influenza A(H1N1) in Germany, Euro Surveill 15

Team I (2010) Start of the influenza season 2010–2011 in Europe dominated by 2009 pandemic influenza A(H1N1) virus, Euro Surveill 15

Haas W (2009) Influenza. Prävention, Diagnostik, Therapie und öffentliche Gesundheit, 1st edn, Elsevier, Urban & Fischer

Gabriel G, Klingel K, Otte A, Thiele S, Hudjetz B, Arman-Kalcek G, Sauter M, Shmidt T, Rother F, Baumgarte S, Keiner B, Hartmann E, Bader M, Brownlee GG, Fodor E, Klenk HD (2011) Differential use of importin-alpha isoforms governs cell tropism and host adaptation of influenza virus. Nat Commun 2:156PubMedCrossRef

Reed LH, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hygiene 27:493–497

Kendal AP, Pereira MS, Skehel JJ (1982) Concepts and procedures for laboratory-based influenza surveillance, distributed by the Viral Diseases Unit. Centers for Disease Control and Prevention, Atlanta

10.

McVernon J, Laurie K, Nolan T, Owen R, Irving D, Capper H, Hyland C, Faddy H, Carolan L, Barr I, Kelso A (2010) Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October–December 2009, Euro Surveill. 15

11.

Nabel GJ, Wei CJ, Ledgerwood JE (2011) Vaccinate for the next H2N2 pandemic now. Nature 471:157–158PubMedCrossRef

12.

Broberg E, Nicoll A, Amato-Gauci A (2011) Seroprevalence to influenza A(H1N1) 2009 virus—where are we? Clin Vaccine Immunol 18:1205–1212PubMedCrossRef

13.

Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, Koh GC, Yap J, Cui L, Cook AR, Laurie K, Tan LW, Tan BH, Loh J, Shaw R, Durrant C, Chow VT, Kelso A, Chia KS, Leo YS (2010) 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 303:1383–1391PubMedCrossRef

14.

Delangue J, Salez N, Ninove L, Kieffer A, Zandotti C, Seston M, Lina B, Nougairede A, Charrel R, Flahault A, de Lamballerie X (2011) Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population, Clin Microbiol Infect

15.

Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, Dwyer DE (2010) Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS ONE 5:e12562PubMedCrossRef

16.

Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361:1945–1952PubMedCrossRef

17.

Kok J, Blyth CC, Foo H, Patterson J, Taylor J, McPhie K, Ratnamohan VM, Iredell JR, Dwyer DE (2010) Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol 48:290–291PubMedCrossRef

18.

Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375:1100–1108PubMedCrossRef

19.

Wu JT, Ma ES, Lee CK, Chu DK, Ho PL, Shen AL, Ho A, Hung IF, Riley S, Ho LM, Lin CK, Tsang T, Lo SV, Lau YL, Leung GM, Cowling BJ, Malik Peiris JS (2010) The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 51:1184–1191PubMedCrossRef

20.

RKI (2009) Aktuelle Daten und Informationen zu Infektionskrankheiten und Public Health. Epidemiologisches Bulletin. Nr. 41, 12th October

21.

RKI (2009) Aktuelle Daten und Informationen zu Infektionskrankheiten und Public Health. Epidemiologisches Bulletin. Nr. 50, 14th December

22.

Adamson WE, Maddi S, Robertson C, McDonagh S, Molyneaux PJ, Templeton KE, Carman WF (2010) 2009 pandemic influenza A(H1N1) virus in Scotland: geographically variable immunity in Spring 2010, following the winter outbreak. Euro Surveill 15

23.

Tsai TF, Pedotti P, Hilbert A, Lindert K, Hohenboken M, Borkowski A, Groth N, da Silva LJ, Kyaw MH (2010) Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August–October 2009. Euro Surveill 15

24.

Reinheimer C, Allwinn R, Doerr HW (2011) Limited prevalence of influenza A/H1N1v antibodies: footprints of the pandemic of 2010. Infection 39:101–104PubMedCrossRef

25.

Reinheimer C, Doerr HW, Friedrichs I, Sturmer M, Allwinn R (2011) H1N1v at a seroepidemiological glance: is the nightmare over? Eur J Clin Microbiol Infect Dis

26.

Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW (2010) Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol 199:117–121PubMedCrossRef

27.

Krumbholz A, Lange J, Durrwald R, Hoyer H, Bengsch S, Wutzler P, Zell R (2010) Prevalence of antibodies to swine influenza viruses in humans with occupational exposure to pigs, Thuringia, Germany, 2008–2009. J Med Virol 82:1617–1625PubMedCrossRef

28.

Walter D, Bohmer MM, Heiden MA, Reiter S, Krause G, Wichmann O (2011) Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10---Results from thirteen consecutive cross-sectional surveys. Vaccine 29:4008–4012PubMedCrossRef

29.

Blank PR, Schwenkglenks M, Szucs TD (2009) Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 58:446–458PubMedCrossRef

30.

Riens B, Mangiapane S, Erhart M, von Stillfried D (2011) Analyse regionaler Unterschiede der Influenza-Impfraten in der Impfsaison 2007/2008. Versorgungsatlas.de

31.

Cramer J, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O, Mertens T, Burchard G (2012) Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. Euro Surveill 17

32.

von Kries R, Weiss S, Falkenhorst G, Wirth S, Kaiser P, Huppertz HI, Tenenbaum T, Schroten H, Streng A, Liese J, Shai S, Niehues T, Girschick H, Kuscher E, Sauerbrey A, Peters J, Wirsing von Konig CH, Ruckinger S, Hampl W, Michel D, Mertens T (2011) Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany. PLoS ONE 6:e23955CrossRef

33.

Wang M, Yuan J, Li T, Liu Y, Wu J, Di B, Chen X, Xu X, Lu E, Li K, Wu Y, He P, Wang Y, Liu J (2011) Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS ONE 6:e16809PubMedCrossRef

Title: Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011
Authors: Anne Hackenberg
Gökhan Arman-Kalcek
Jens Hiller
Gülsah Gabriel
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Medical Microbiology and Immunology / Issue 1/2013
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-012-0251-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia

Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling

Infection of neutrophil granulocytes with Leishmania major activates ERK 1/2 and modulates multiple apoptotic pathways to inhibit apoptosis

IFNγ expression by an attenuated strain of Salmonella enterica serovar Typhimurium improves vaccine efficacy in susceptible TLR4-defective C3H/HeJ mice

Bacterial TIR-containing proteins and host innate immune system evasion

Performance evaluation of a new fourth-generation HIV combination antigen–antibody assay

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page